Gefitinib shows promise in treating Asian nonsmokers with lung cancerSeptember 16th, 2008 - 1:28 pm ICT by ANI
Washington, Sept 16 (ANI): Researchers in Hong Kong have suggested that gefitinib should be considered a first-line therapy for non-smoking Asian patients with one of the most common types of lung cancer adenocarcinoma.
Asia has a high proportion of lung cancer patients, who are non-smokers, a significant proportion of whom develop a form of cancer known as adenocarcinoma.
“Around 50 percent to 60 percent of this population have tumours with mutations in the epidermal growth factor receptor, and we know that patients with such mutations have a significantly better treatment outcome with gefitinib,” said Prof. Tony Mok from the Chinese University of Hong Kong.
“Currently, gefitinib and other EGFR tyrosine kinase inhibitors are considered as second line therapy for advanced non-small-cell lung cancers, meaning that the drugs should only be used after cancers fail to respond to the standard cytotoxic chemotherapy,” Mok added.
For the study, Mok and colleagues examined 1,217 lung cancer patients who had never received chemotherapy and had never smoked or were light ex-smokers.
Half the group was treated with gefitinib 250 mg/day or a combination of carboplatin and paclitaxel.
Over 22 months of follow-up, the researchers found that gefitinib was more tolerable and resulted in a greater likelihood of response.
“We have demonstrated better treatment outcomes with gefitinib over standard chemotherapy as first-line therapy for this clinically selected population,” Mok said.
“Our study has established the role of gefitinib as one of the standard first-line therapies for a clinically selected group of non-/light smokers with adenocarcinoma,” Mok added.
The study was presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm. (ANI)
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Skin rash linked to better outcomes for patients with lung cancer - Dec 20, 2010
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- Molecule key to non-smoking lung cancer identified - Jul 28, 2009
- Targeted drug therapy shows promise against deadly form of lung cancer - Nov 02, 2010
- Smokers '7 times more likely to get lung cancer than non-smokers' - Dec 16, 2010
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
- Diets high in fish oil 'help maintain weight during chemotherapy' - Feb 28, 2011
- Potential new method for early lung cancer detection - Oct 06, 2010
- Cheek swab may spot lung cancer - Oct 08, 2010
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Cetuximab drug with chemo may cut death risk in lung cancer patients - Sep 22, 2009
- Don't ignore that jagged tooth! - Oct 17, 2010
- Simple blood test could provide early detection of emphysema - Mar 12, 2011
Tags: adenocarcinoma, asian patients, carboplatin, cell lung, chinese university of hong kong, cytotoxic, epidermal growth factor, epidermal growth factor receptor, gefitinib, growth factor receptor, lung cancer, lung cancer patients, lung cancers, mok, nonsmokers, paclitaxel, treatment outcome, treatment outcomes, types of lung cancer, tyrosine kinase inhibitors